Exelixis
EXEL
#1563
Rank
โ‚น1.357 T
Marketcap
โ‚น5,400
Share price
1.06%
Change (1 day)
41.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น280.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น301.18. In 2025 the company made an earnings per share (EPS) of โ‚น278.09.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น280.560.89%
2025โ‚น278.09
2023โ‚น62.8614.61%
2022โ‚น54.85-22.97%
2021โ‚น71.21100%
2020โ‚น35.60-65.09%
2019โ‚น102.00-53.91%
2018โ‚น221.32333.96%
2017โ‚น51.00-260.61%
2016-โ‚น31.75-58.75%
2015-โ‚น76.98-42.45%
2014-โ‚น133.755.3%
2013-โ‚น127.02

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น840.66 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น126.05-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,393 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น246.30-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น342.31 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น342.56 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น373.96 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น353.15-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น80.83-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA